Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Epistasis Analysis01:09

Epistasis Analysis

Although Mendel chose seven unrelated traits in peas to study gene segregation, most traits involve multiple gene interactions that create a spectrum of phenotypes. When the interaction of various genes or alleles at different locations influences a phenotype, this is called epistasis. Epistasis often involves one gene masking or interfering with the expression of another (antagonistic epistasis). Epistasis often occurs when different genes are part of the same biochemical pathway. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ganglion impar block in chronic cancer-related pain - A review of the current literature.

Revista espanola de anestesiologia y reanimacion·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine.

Pulmonology·2023
Same author

SKELETAL MUSCLE SENSITIVITY TO WASTING INDUCED BY UROTHELIAL CARCINOMA.

Experimental oncology·2023
Same author

Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia.

ESMO open·2023
Same author

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.

ESMO open·2023
Same journal

Neuromuscular electrical stimulation after anterior cruciate ligament reconstruction.

International journal of sports medicine·2026
Same journal

Exercise Intensity Effects on Irisin in Master Athletes and Links With Maximal Oxygen Uptake and Body Fat.

International journal of sports medicine·2026
Same journal

Evolution of the Australian Institute of Sport Supplement Program over the last 25 years.

International journal of sports medicine·2026
Same journal

Preseason Passive Torque Asymmetries in Soccer Players with Hamstring Strain Injury.

International journal of sports medicine·2026
Same journal

Musculoskeletal Burden in German Equestrians: Hip-Specific Symptoms and Risk Factors.

International journal of sports medicine·2026
Same journal

Trans-inclusion in sports: history, scientific evidence and future directions.

International journal of sports medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Is there an ACE ID - ACTN3 R577X polymorphisms interaction that influences sprint performance?

N Eynon1, A J Alves, C Yamin

  • 1Zinman College of Physical Education and Sports Sciences at the Wingate Institute, Genetics and Molecular Biology, Netanya, Israel. eynon@wincol.ac.il

International Journal of Sports Medicine
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Sprint performance is linked to specific gene variations. The ACTN3 RR genotype with the ACE I allele, and the ACE II genotype with the ACTN3 R allele, are associated with being a sprinter.

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

Related Experiment Videos

Last Updated: Jun 17, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

Area of Science:

  • Genetics
  • Sports Science
  • Human Performance

Background:

  • The alpha-actinin-3 (ACTN3) R577X polymorphism and the angiotensin converting enzyme (ACE) ID polymorphism are known to influence athletic performance.
  • Understanding the combined effects of these genetic variations on sprint ability is crucial for sports science research.

Purpose of the Study:

  • To investigate the association between ACTN3 R577X and ACE ID gene polymorphisms and sprint performance in Israeli athletes.
  • To determine if specific genotype combinations predict sprint ability.

Main Methods:

  • Case-control study involving 81 sprinters and 240 healthy controls.
  • Genotyping for ACTN3 R577X (rs1815739) and ACE ID (rs5186) polymorphisms.
  • Statistical analysis including odds ratios and confidence intervals to assess genotype-phenotype associations.

Main Results:

  • The ACE II genotype combined with the ACTN3 R allele showed a significant association with sprinters compared to controls (P=0.003).
  • The ACTN3 RR genotype combined with the ACE I allele also showed a significant association with sprinters (P=0.001).
  • Individuals with ACTN3 RR + ACE I allele (OR 2.67) and ACE II + ACTN3 R allele (OR 3.57) had a significantly higher probability of being sprinters.

Conclusions:

  • Specific combinations of ACTN3 R577X and ACE ID genotypes are associated with sprint ability.
  • These genotype combinations increase the likelihood of an individual being a sprinter but do not correlate with the elite level of performance.